Similar articles

• Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.

  Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni L, Page RL 2nd, Kobashigawa J. Lindenfeld J, et al. Circulation. 2004 Dec 21;110(25):3858-65. doi: 10.1161/01.CIR.0000150332.42276.69. Circulation. 2004. PMID: 15611389 Review. No abstract available.
• Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.

  Knight RJ, Podder H, Kerman RH, Lawless A, Katz SM, Van Buren CT, Gaber AO, Kahan BD. Knight RJ, et al. Transplantation. 2010 Mar 27;89(6):727-32. doi: 10.1097/TP.0b013e3181c9dc9b. Transplantation. 2010. PMID: 20195219
• [Association of everolimus with tacrolimus during the first year after heart transplantation: initial experience].

  Cardona M, Castel MÁ, Farrero M, Pérez-Villa F. Cardona M, et al. Med Clin (Barc). 2013 Jul 21;141(2):87-8. doi: 10.1016/j.medcli.2012.12.003. Epub 2013 Feb 4. Med Clin (Barc). 2013. PMID: 23384432 Spanish. No abstract available.
• Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.

  Ekberg H, Bernasconi C, Nöldeke J, Yussim A, Mjörnstedt L, Erken U, Ketteler M, Navrátil P. Ekberg H, et al. Nephrol Dial Transplant. 2010 Jun;25(6):2004-10. doi: 10.1093/ndt/gfp778. Epub 2010 Jan 26. Nephrol Dial Transplant. 2010. PMID: 20106825 Clinical Trial.
• Conversion to sirolimus.

  Ruiz JC, Alonso A, Arias M, Campistol JM, González Molina M, González Posada JM, Grinyo JM, Morales JM, Oppenheimer F, Sánchez Fructuoso A, Sánchez-Plumed J. Ruiz JC, et al. Nefrologia. 2006;26 Suppl 2:52-63. Nefrologia. 2006. PMID: 17937634 Review. English, Spanish. No abstract available.